Mei Dong - Concepedia

Author

Mei Dong

Third Affiliated Hospital of Harbin Medical University ORCID

Also Known As

Dong M, Dong Mei, M Dong, M. Dong, MEI DONG, Mei Dong

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

Third Affiliated Hospital of Harbin Medical University Harbin Medical University Duke Medical Center Duke University Hospital Chinese Academy of Medical Sciences & Peking Union Medical College

About

Mei Dong is an author at Third Affiliated Hospital of Harbin Medical University specializing in medicine, oncology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	783
2	Cell Biology	6	6	364
3	Immunology	3	3	351
4	Cellular Physiology	2	2	43
5	Health Sciences	1	1	20

Mei Dong

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity Zhiqiang Ning, Zhibin Li, Michael Newman, Cancer Chemotherapy and Pharmacology Antitumor ActivityMedicineImmunologyPharmacologyImmune Checkpoint Inhibitor	2011	284
The type III TGF-β receptor suppresses breast cancer progression Mei Dong, Tam How, Kellye C. Kirkbride, Journal of Clinical Investigation	2006	253
PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors Funda Meric‐Bernstam, Argun Akçakanat, Huiqin Chen, Clinical Cancer Research	2012	207
Loss of Betaglycan Expression in Ovarian Cancer: Role in Motility and Invasion Nadine Hempel, Tam How, Mei Dong, Cancer Research Ovarian Cancer MotilityOncologyMedicineCancer GrowthGynecology	2007	129
Loss of type III transforming growth factor β receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression Kelly J. Gordon, Mei Dong, Elizabeth M. Chislock, Carcinogenesis PathologyCancer BiologyTumor BiologySignaling PathwayPancreatic Cancer	2007	124
Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas Mei Dong, Zhiqiang Ning, Pu-yuan Xing, Cancer Chemotherapy and Pharmacology Lymphoid NeoplasiaOncologyMedicinePathologyAdvanced Solid Tumors	2012	120
TβRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity Elizabeth Finger, Ryan S. Turley, Mei Dong, Carcinogenesis	2008	111
Long non-coding RNA NEAT1 regulates E2F3 expression by competitively binding to miR-377 in non-small cell lung cancer Junsheng Zhang, Yongli Li, Mei Dong, Oncology Letters	2017	83
Inverse association between phospholipase A2 and COX-2 expression during mouse colon tumorigenesis Mei Dong Carcinogenesis	2003	75
Expression of the type III TGF-β receptor is negatively regulated by TGF-β Nadine Hempel, Tam How, Simon Cooper, Carcinogenesis Immune RegulationImmunologyCancer BiologyMammary Gland DevelopmentTumor Biology	2008	48

Page 1